Amneal Pharmaceuticals (AMRX) announced the FDA has approved the company’s iohexol injection, the first generic version of GE Healthcare’s Omnipaque injection. Amneal expects to launch the product in the first quarter of 2026.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals Reports Strong Q3 Growth Amid Challenges
- Amneal Pharmaceuticals price target raised to $13 from $11 at Piper Sandler
- Amneal Pharmaceuticals Reports Strong Q3 2025 Results
- Amneal Pharmaceuticals reports Q3 adjusted EPS 17c, consensus 14c
- Amneal Pharmaceuticals raises 2025 adjusted EPS view to 75c-80c from 70c-75c